Between celebrating the Canadian approval of Seroquel to treat major depression, then learning the the Netherlands denied approval for the same, AstraZeneca has had quite a ride. In the courts a similar see-saw is taking place. A judge dismissed a case in Del. charging diabetes was the result of Seroquel This is the third case dismissed, and the only potential jury trial. They have drawn considerable attention and new cases are scheduled in New Jersey and New York. Documents have been released showing drug company withheld information about side effects, but plaintiffs have had difficulty persuading judges that the Seroquel caused their diabetes, a disorder with numerous risk factors. Several revenue generating drugs are scheduled to lose patent protection by 2012, including Seroquel, with sales estimated around $4.4 billion.
Consider This
by Phyllis Vine
MIWatch.org on Facebook
Relevant Sites
- Visit the Illinois neurology department of Northshore
Featured Videos
Most Popular
MIWatch Archives
This site complies with the HONcode standard for trustworthy health information:
verify here.
